Biomarkers and Actionable Gene Mutations in Gastrointestinal Cancer



 

Dr. Matkowskyj will review the role and repertoire of current biomarkers in gastrointestinal cancers including actionable mutations and alterations. She will provide real world examples of current biomarkers and their impact on clinical outcomes. Dr. Matkowskyj will share her personal experience with a recently approved companion diagnostic biomarker and conclude her talk with emerging biomarkers in the gastric cancer space.

Originally published on July 2, 2025


Lecture Presenter

Kristina A. Matkowskyj, MD, PhD

Kristina A. Matkowskyj, MD, PhD

Senior Associate Consultant, Laboratory Medicine and Pathology
Mayo Clinic

Dr. Matkowskyj attended the University of Illinois in Chicago for her graduate and medical school degrees and then completed her anatomic pathology residency and GI/liver pathology fellowship at Northwestern University/McGaw Medical Center in Chicago. She is a board-certified anatomic pathologist, who practiced at the University of Wisconsin-Madison for 12 years. She recently relocated and is a professor in the Department of Laboratory Medicine at Mayo Clinic in Rochester, Minnesota. She serves on several NIH review panels, and is a member of the CAP Cancer Committee and the Gastric HER2 Guidelines Panel. She previously served as a member of the NCCN Guideline panels for esophageal and gastric cancers. Dr. Matkowskyj’s research focuses on novel biomarkers and experimental therapeutics in gastrointestinal and pancreaticobiliary malignancies.


Objectives

After this presentation, participants will be able to:

  • Review several existing biomarkers within the GI cancer space
  • Discuss a novel biomarker for a recently approved companion diagnostic
  • Review findings on emerging biomarkers in gastric carcinoma

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories